Globus Medical (GMED) EBIAT (2016 - 2025)
Globus Medical (GMED) has disclosed EBIAT for 15 consecutive years, with $140.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 430.44% year-over-year to $140.6 million, compared with a TTM value of $537.9 million through Dec 2025, up 422.28%, and an annual FY2025 reading of $537.9 million, up 422.28% over the prior year.
- EBIAT was $140.6 million for Q4 2025 at Globus Medical, up from $119.0 million in the prior quarter.
- Across five years, EBIAT topped out at $202.8 million in Q2 2025 and bottomed at -$7.1 million in Q1 2024.
- Average EBIAT over 5 years is $55.2 million, with a median of $47.3 million recorded in 2021.
- Peak annual rise in EBIAT hit 5093.99% in 2024, while the deepest fall reached 114.49% in 2024.
- Year by year, EBIAT stood at $15.1 million in 2021, then soared by 231.42% to $50.1 million in 2022, then plummeted by 69.97% to $15.0 million in 2023, then surged by 76.3% to $26.5 million in 2024, then surged by 430.44% to $140.6 million in 2025.
- Business Quant data shows EBIAT for GMED at $140.6 million in Q4 2025, $119.0 million in Q3 2025, and $202.8 million in Q2 2025.